| Nature of business | The Company owns and operates a modern pharmaceuticals factory and produces and sells pharmaceuticals drugs and medicine. |
| Reason for IPO | For construction of expansion project of Orion Pharma Limited at Valuka, Mymensingh in terms of the expansion of the existing product line along with the addition of new product lines. |
| Subscription open | 06 Jan 2013 |
| Subscription close | 10 Jan 2013 |
| Subscription close for NRB | 06 Jan 2013 to 19 Jan 2013 |
| Offer price | Tk. 60.0 |
| Face value per share | Tk. 10.0 |
| Market lot | 100 units |
| Single lot price | Tk. 6000.0 |
| EPS | Tk. 5.57 for the year ended December 31, 2011. |
| NAV | Tk. 76.87 (considering revaluation reserve) as on December 31, 2011. Tk. 61.43 (without revaluation reserve) as on December 31, 2011. |
| Public offer | 40,000,000 |
| Major product | Enliven (Imatinib Mesylate) capsule, Betacal (Atenolol plus amlodipine) tab, Vertex injection (Ceftriaxone sodium), Clognil plus (Clopidogrel+ Aspirin) tab, Pep (Zinc sulphate) Tab/Syrup, Deslor (Desloratadine) Tab/Syp, Axet (Cefuroxime) Tab/inj, Pedicef (Cefpodoxime) susp, Azalid (Azithromycin) Tab/Sus, Truso (Cefixime) Cap/sus. |
| Issue Manager | ICB Capital Management Limited |
| Website | www.orion-group.net |
Share with friends
